Leukemias related to treatment with DNA topoisomerase II inhibitors

Medical and Pediatric Oncology

Volumn 36, Issue 5, 2001, Pages 525-535

  Felix, Carolyn A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Anthracycline; Epipodophyllotoxin; MLL gene; Secondary leukemia; Translocations

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; DACTINOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIPODOPHYLLOTOXIN; GYRASE INHIBITOR; TENIPOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 11Q; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; COMPLEX FORMATION; CONFERENCE PAPER; CYTOTOXICITY; DNA CLEAVAGE; DNA DAMAGE; DNA HELIX; DNA REPAIR; GENETIC PREDISPOSITION; HUMAN; INCIDENCE; LEUKEMIA; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; HUMANS; LEUKEMIA; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PROTO-ONCOGENES; SURVIVORS; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 0035056832     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.1125     Document Type: Conference Paper

References (157)

1. The secondary leukemias: Challenges and research directions
2. Patterns of second cancers
3. Acute lymphoblastic leukaemia with t(4;11) follows neuroblastoma: A late effect of treatment
4. Translocation (9;11)(p21q23) in a child with acute monoblastic leukemia following 2 1/2 years after successful chemotherapy for neuroblastoma
5. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung
6. Report of the clinical therapy evaluation program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins
7. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks
8. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins
9. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia
10. Myeloid neoplasia in children treated for solid tumours
11. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia
12. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide
13. Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung
14. Acute nonlymphocytic leukemia after treatment of small cell lung cancer
15. Implications of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocation
16. Acute nonlymphoblastic leukemia in children treated for acute lymphoblastic leukemia with an intensive regimen including teniposide
17. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III An interim report
18. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q
19. Epipodophyllotoxin-related leukemia: Identification of a new subset of secondary leukemia
20. Secondary leukaemias after etoposide
21. Secondary leukaemia after epipodophyllotoxins
22. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer
23. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia
24. Secondary leukemia associated with a conventional dose of etoposide: Review of serial germ cell tumor protocols
25. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy
26. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours
27. Secondary pre-leukaemia and etoposide
28. Acute leukemia after successful chemotherapy for oat cell carcinoma
29. Secondary neoplasms following treatment of malignant germ cell tumors
30. MLL is fused to CBP, a histone acetyltransferase, in therapy related acute myeloid leukemia with a t(11;16)(q23;p13.3)
31. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene
32. Transient therapy-related myelodysplastic syndrome associated with monosomy 7 and 11q23 translocation
33. Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: Report of three cases and review of the literature
34. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11)
35. Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias
36. Chemotherapy-related - And late occurring - Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors?
37. IARC Monographs on the evaluation of carcinogenic risks to humans
38. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: A Pediatric Oncology Group study
39. High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma
40. Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer
41. Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer
42. Secondary tumours following etoposide containing therapy for germ cell cancer
43. When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by antineoplastic drugs
44. Epipodophyllotoxins in the treatment of childhood cancer
45. The European Organization for Research and Treatment of Cancer experience with teniposide: Preliminary results of a randomized study in non-small cell lung cancer
46. Teniposide: Overview of its therapeutic potential in adult cancers
47. Treatment of small cell lung cancer: The Copenhagen experience
48. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia
49. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epidoxorubicin and cisplatin or cyclophosphamide for breast cancer
50. Therapy-related acute promyelocytic leukemia: A report on 16 cases
51. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation
52. Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints
53. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors
54. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis
55. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II
56. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites
57. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints
58. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors
59. DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis
60. Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AMLI locus
61. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia
62. Chromosome translocations and leukemias induced by inhibitors of topoisomerase II anticarcinogenic drugs
63. The epipodophyllotoxins: Both sides of the coin
64. Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia
65. L-Asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins
66. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations
67. LCH-I: A randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis
68. Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis
69. Acute leukemia in association with Langerhans' cell histiocytosis
70. Neuroblastoma and treatment-related myelodysplasia/leukemia: The memorial sloan-kettering experience and a literature review
71. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors
72. Malignancies after hematopoietic stem cell transplantation: Many questions, some answers
73. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors
74. The p53 gene in pediatric therapy-related leukemia and myelodysplasia
75. Emergence of secondary acute leukemia in a patient treated for osteosarcoma: Implications of germline TP53 mutations
76. Association of germline p53 replication error with myelodysplastic syndrome following osteosarcoma treatment
77. Potential role for wild-type p53 in leukemias with MLL gene translocations
78. Substrates of human hepatic cytochrome P450 3A4
79. Mechanism of action of antitumor drug etoposide: A review
80. Role of the semi-quinone free radical of the anti-tumour agent etoposide (VP-16-213) in the inactivation of single- and double-stranded fc 174 DNA
81. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4
82. Structure-activity relations, cytotoxicity and topoisomerase II dependent cleavage induced by pendulum ring analogues of etoposide
83. The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex
84. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: Ethnic distribution and implications for prostate cancer risk
85. Association of CYP3A4 genotype with treatment-related leukemia
86. Considerable plasma levels of a cytotoxic etoposide metabolite in patients undergoing high-dose chemotherapy
87. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies
88. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia
89. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations
90. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy
91. Rearrangements involving chromosome band 11q23 in acute leukemia
92. 11q23 Rearrangements in acute leukemia
93. Epipodophyllotoxin-related acute myeloid leukemia: A study of 35 cases
94. Infant cancer in the U.S.: Histology-specific incidence and trends, 1973-1992
95. Leukemia in infants
96. Biological and therapeutic aspects of infant leukemia
97. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children
98. Panhandle PCR for cDNA: A rapid method for isolation of MLL fusion transcripts involving unknown partner genes
99. A Trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukemias
100. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene
101. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias
102. Analysis of the murine All-1 gene reveals conserved domains with human ALL-1 and identifies a motif shared with DNA methyltransferases
103. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product
104. Complete exon structure of the ALL1 gene
105. Defects in yolk-sac hematopoiesis in Mll-null embryos
106. Double knockout of the ALL-1 gene blocks hematopoietic differentiation in vitro
107. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes
108. Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloid leukemia
109. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA topoisomerase II
110. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11)
111. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: Correlation with scaffold attachment regions and topoisomerase II consensus binding sites
112. Novel SH3 protein encoded by the AF3p21 gene is fused to the mixed lineage leukemia protein in a therapy-related leukemia with t(3;11) (p21 ;q23)
113. t(3;11)(q25;q23) in treatment-related acute myeloid leukemia fuses MLL gene with GMPS (Guanosine 5′-monophosphate synthetase)
114. AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily
115. All patients with t(11;16)(q23;p13.3) that involve MLL and CBP have treatment-related hematologic disorders
116. MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25)
117. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22) (q23;q13)
118. Secondary leukemias induced by topoisomerase targeted drugs
119. Self-fusion of the ALL1 gene
120. Resistance of t(4;11)(MLL-AF4 fusion gene) leukemia to stress-induced cell death: Possible mechanism for extensive extramedullary accumulation of cells and poor prognosis
121. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants
122. When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by anti-neoplastic drugs
123. Induction of topoisomerase I cleavage complexes by 1-b-D-arabinofurano-sylcytosine (ara-C) in vitro and in ara-C-treated cells
124. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region
125. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia
126. The association of specific "favorable" cytogenetic abnormalities with secondary leukemia
127. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): A report on 25 cases and review of the literature
128. Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia
129. t(3;21)(q26;q22): A recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia
130. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis
131. CBFA2 (AML1) translocations with novel partner chromosomes in myeloid leukemias: Association with prior therapy
132. Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia
133. The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute to malignant transformation
134. Favorable cytogenetic abnormalities in secondary leukemia
135. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors
136. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia
137. Two distinct loci on the short arm of chromosome 16 are involved in myeloid leukemia
138. The translocation t(8;16)(p11;p13) of acute myeloid leukemia fuses a putative acetyltransferase to the CREB-binding protein
139. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP
140. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis
141. Acute promyelocytic leukemia following treatment of non-Hodgkin's lymphoma
142. Secondary acute promyelocytic leukemia in a child treated with epipodophyllotoxins
143. Acute promyelocytic leukemia after treatment of malignant glioma in a patient with Von Recklinghausen's disease: A case report and review of the literature
144. The peptide repeat domain of nucleoporin NUP98 functions as a docking site in transport across the nuclear pore complex
145. Involvement of 11p15 and 2q21q26 in therapy-related myeloid leukemia (t-ML) in children
146. Inversion of chromosome 11 inv(11)(p15q22), as a recurring chromosomal aberration associated with de novo and secondary myeloid malignancies: Identification of a P1 clone spanning the 11q22 breakpoint
147. NUP98HOXD13 gene fusion in therapy-related acute myelogenous leukemia
148. The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, NUP98, with a putative RNA helicase gene, DDX10
149. Fusion of the nucleoporin gene NUP98 to HOXA9 by chromosomal translocation t(7;11)(p15;p15) in human myeloid leukemia
150. The t(7;11) (p15;p15) translocation in acute myeloid leukemia fuses the genes for nucleoporin NUP98 to class I homeoprotein HOXA9
151. NUP98 is fused to PMXI homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15)
152. The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene NUP98 with the putative RNA helicase gene DDX10
153. The t(11;20)(p15;11q) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in NUP98-TOP1 fusion
154. Stem cell transplantation for secondary acute myeoid leukemia: Evaluation of transplantation as initial therapy or following induction chemotherapy
155. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients-report of the French society of bone marrow transplantation
156. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia
157. Acute promyelocytic leukemia: From genetics to treatment